09:01 AM EST, 02/24/2025 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday that the US Food and Drug Administration has approved its Ctexli tablets, a bile acid treatment for adults with cerebrotendinous xanthomatosis, a rare genetic disorder that impairs cholesterol breakdown.

The company said the approval is based on late-stage trial data showing Ctexli significantly reduced bile alcohols, addressing a deficiency of chenodeoxycholic acid in patients.

Ctexli will be available through Mirum's patient support program, Mirum Access Plus, the company said.